| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Fennec Pharmaceuticals Inc. ("Issuer")
13G/A
Amendment 4
FENC · 31447P100
|
4.5% |
11/16/2026
Event 9/30/2026
|
|||
| Sonic Fund II, L.P. | 4.1% | ||||
| Sonic GP LLC | 4.1% | ||||
| Lawrence Kam | 4.5% | ||||
|
Fennec Pharmaceuticals Inc.
13G/A
Amendment 3
FENC · 31447P100
|
8.2% |
2/17/2026
Event 12/31/2025
|
|||
| Sonic Fund II, L.P. | 7.6% | ||||
| Sonic GP LLC | 7.6% | ||||
| Kam Lawrence | 8.2% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.